Pediatrix Medical Group (NYSE:MD) Reaches New 52-Week High After Better-Than-Expected Earnings

Pediatrix Medical Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Pediatrix Medical Group reached a new 52-week high of $30.55 after reporting quarterly EPS of $0.72, surpassing analyst estimates of $0.65. Revenue rose 1.7% year over year to $501.37 million, also exceeding expectations.
  • Analysts remain cautious, with one Buy rating and five Hold ratings; the consensus target price is $26.60, below the stock’s recent trading level.
  • Institutional ownership is substantial at 97.71%, with major investors including BlackRock, Dimensional Fund Advisors, Wasatch Advisors and Renaissance Technologies holding or increasing positions.
  • MarketBeat previews top five stocks to own in December.

Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) reached a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $30.55 and last traded at $29.3750, with a volume of 25,767 shares. The stock had previously closed at $28.91.

The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.07. The business had revenue of $501.37 million during the quarter, compared to analyst estimates of $498.18 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company's revenue was up 1.7% on a year-over-year basis. During the same period last year, the firm posted $0.67 EPS.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on MD shares. Truist Financial lifted their target price on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a "hold" rating in a research report on Tuesday, July 14th. Jefferies Financial Group lowered Pediatrix Medical Group from a "buy" rating to a "hold" rating and upped their target price for the company from $27.00 to $28.00 in a research report on Wednesday, August 19th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $25.00 price objective on shares of Pediatrix Medical Group in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised shares of Pediatrix Medical Group from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of "Hold" and an average target price of $26.60.

Check Out Our Latest Analysis on MD

Institutional Trading of Pediatrix Medical Group

A number of institutional investors and hedge funds have recently bought and sold shares of MD. BlackRock Inc. purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at $347,383,000. Dimensional Fund Advisors LP boosted its position in shares of Pediatrix Medical Group by 8.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,856,915 shares of the company's stock worth $82,496,000 after buying an additional 287,696 shares in the last quarter. Wasatch Advisors LP grew its stake in Pediatrix Medical Group by 21.9% in the 2nd quarter. Wasatch Advisors LP now owns 2,498,884 shares of the company's stock valued at $63,297,000 after acquiring an additional 448,360 shares during the last quarter. Renaissance Technologies LLC grew its stake in Pediatrix Medical Group by 12.9% in the 1st quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company's stock valued at $32,776,000 after acquiring an additional 174,600 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in Pediatrix Medical Group by 52.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 975,133 shares of the company's stock valued at $20,185,000 after acquiring an additional 335,733 shares during the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Price Performance

The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32. The stock has a market capitalization of $2.39 billion, a PE ratio of 14.05 and a beta of 0.61. The company's fifty day simple moving average is $26.80 and its two-hundred day simple moving average is $23.79.

About Pediatrix Medical Group

(Get Free Report)

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company's clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pediatrix Medical Group Right Now?

Before you consider Pediatrix Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.

While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines